hcp.obgyn.net Members: Login | Register
OBGYN.net Recommended Medical Sites Medline Drugs

Powered by SearchMedica

 
  • Home
  • News
  • Blogs
  • Calendar
  • Conditions and Procedures
  • Conferences
  • Tutorials
  • Forum
  • Ultrasound
  • Buyer's Guide

 

Intercellular Adhesion Molecule-1 Expression in Human Endometrium

By Frederick Schatz 1, Graciela Krikun 1, Rebecca N Baergen 2, Hilary OD Critchley 3, Edward Kuczynski 1 and Charles J Lockwood 1
1 Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven CT, USA
2 Department of Pathology, Weil-Cornell Medical Center, New York NY, USA
3 Centre for Reproductive Biology, University of Edinburgh, UK | July 12, 2011

Reproductive Biology and Endocrinology 2006 by BioMed Central
An Open Access Research article
Published 30 January 2006

Background
Neutrophils infiltrate the endometrium pre-menstrually and after long-term progestin only-contraceptive (LTPOC) treatment. Trafficking of neutrophils involves endothelial cell-expressed intercellular adhesion molecule (ICAM-1). Previous studies observed that ICAM-1 was immunolocalized to the endothelium of endometrial specimens across the menstrual cycle, but disagreed as to whether extra-endothelial cell types express ICAM-1 and whether ICAM-1 expression varies across the menstrual cycle.

Methods
Endometrial biopsies were obtained from women across the menstrual cycle and from those on LTPOC treatment (either Mirena or Norplant). The biopsies were formalin-fixed and paraffin(Drug information on paraffin)-embedded with subsequent immunohistochemical staining for ICAM-1.

Results
The current study found prominent ICAM-1 staining in the endometrial endothelium that was of equivalent intensity in different blood vessel types irrespective of the steroidal or inflammatory endometrial milieu across the menstrual cycle and during LTPOC therapy. Unlike the endothelial cells, the glands were negative and the stromal cells were weakly positive for ICAM immunostaining.

Conclusion
The results of the current study suggest that altered expression of ICAM-1 by endothelial cells does not account for the influx of neutrophils into the premenstrual and LTPOC-derived endometrium. Such neutrophil infiltration may depend on altered expression of neutrophil chemoattractants.

Background
The premenstrual human endometrium displays increased prostaglandin-generating capacity, elevated levels of inflammatory cytokines [1,2] and a leukocyte infiltrate that comprises nearly one-half of the cell population [3-5]. Among endometrial leukocyte subtypes, neutrophils are virtually absent until the mid-luteal phase, but comprise a significant portion of the leukocytes in the menstrual phase. During long-term progestin-only contraceptive (LTPOC) administration, the endometrium also experiences enhanced prostaglandin-generating capacity and increased inflammatory cytokine levels [6,7]. Administration of Norplant, which releases levonorgestrel(Drug information on levonorgestrel) (LNG) from subdermal rods, and Mirena, which releases LNG from an intrauterine system, leads to endometrial infiltration of matrix metalloproteinase-9 (MMP-9) positive neutrophils [8], and macrophages [9], respectively.

Endothelial cell-expressed cellular adhesion molecules mediate leukocyte trafficking [10]. In this regard, particular attention has been directed at the physiological and pathological roles played by intercellular adhesion molecule (ICAM-1), a 76-114-kDa surface glycoprotein that has five extracellular immunoglobulin-like domains [11-14].Transmigration of leukocytes involves high-affinity binding of LFA-1 or Mac-1 on their surface to ICAM-1 expressed on the endothelium [10]. ICAM-1 deficient mice experience numerous inflammatory response abnormalities including impaired neutrophil trafficking [15,16]. Although ICAM-1 has been immunolocalized to the endothelium of various blood vessel types in specimens of cycling endometrium, there are conflicting reports as to whether extra-endothelial cell types also express ICAM-1, and whether ICAM-1 expression varies across the menstrual cycle [17-19]. In view of this lack of consensus, the current study reassessed immunohistochemical (IHC) staining for ICAM-1 in endometrial biopsies across the menstrual cycle, and extended the use of IHC staining of ICAM-1 to include endometrial tissues exposed to subdermal (Norplant) and intra-uterine (Mirena, Schering) exogenous progestogens. Both LTPOC types provide safe and effective contraception for several years. Norplant is particularly well suited for use in underdeveloped countries where access to trained medical personnel is limited. They are discontinued primarily because of inflammation-associated abnormal uterine bleeding (AUB) as a source of personal annoyance and discomfort as well as cultural and religious taboo [20,21]. The levonorgestrel-releasing intra-uterine system (LNG-IUS, Mirena) is now increasingly used as an effective contraceptive and for its associated health benefits, including reduction in menstrual blood loss [22].

Prior to menstruation and during progestin-only contraception (Norplant, Mirena), secretion of MMPs by endometrial leukocytes as well as cytokines that can act as autocrine/paracrine modulators of MMP expression [5], are thought to enhance degradation of the vascular support structure leading to stromal collapse and bleeding [23-26]. The current study sought to determine whether altered expression of ICAM-1 could account for infiltration of neutrophils into the menstrual and LTPOC-derived endometrium.

Methods

Tissues
After receiving written informed consent and approval from the Institutional Research Board (IRB) of New York University Medical Center and Bellevue Hospital, specimens of endometrium were obtained across the menstrual cycle (four each from the follicular and luteal phases and five from the menstrual phase) from hysterectomies for benign conditions (e.g. myomas without abnormal uterine bleeding), and histologically dated by the criteria of Noyes et al [27]. For studies on LTPOC-derived endometrium, institutional ethical review and approval was obtained from the New York University IRB and the Lothian Research Ethical Committee, Scotland and written informed consent was obtained for biopsy collection.

The subjects had regular menstrual cycles and had not used hormonal or intrauterine contraception in the six months prior to insertion of Norplant or Mirena. Patients did not exhibit symptoms characteristic of endometriosis such as pelvic pain, dysmennorhea, dysparunia, or infertility. The only way to confirm a diagnosis of endometriosis is through exploratory surgery. Such surgery would be prompted by symptoms that would have ruled out the use of those patients for our study. For the cycling endometrium patients were pre-menopausal between 32 and 43 years of age who were not receiving any hormonal treatments. For the LTPOC endometrium patients were premenopausal, between 28 and 45 years of age, had regular menstrual cycles and had not used any hormonal or intrauterine contraception in the six months prior to receiving the LTPOC treatment.

Norplant specimens
Prior to insertion of Norplant biopsies were collected from four women (two in the follicular and two in the luteal phase) by Pipelle suction curette (Laboratoire CCD, Paris, France). Only patients who experienced bleeding while on the Norplant treatment were used. Biopsies were collected using an operative hysteroscope connected to a video camera to facilitate separate sampling of bleeding and non-bleeding sites as previously described [25]. These samples were taken after 3 and 12 months post Norplant insertion

Mirena specimens
Endometrial biopsies were also obtained from four women (two in the follicular and two in the luteal phase) prior to and at 1, 3, 6, and 12 months after intrauterine insertion of the LNG-intrauterine system by Pipelle suction biopsy.

Immunohistochemistry (IHC)
Specimens of endometrium obtained across the menstrual cycle as well as from control, and levonorgestrel treated (Norplant, Mirena) subjects were fixed in 4% paraformaldehyde and embedded in paraffin. Four μm sections (4 μm) were deparaffinized, rehydrated and washed in Tris-buffered saline [TBS: 20 mmol/l Tris-HCl, 150 mmol/l NaCl (pH 7.6)], which was used for all washes and for dilution of the antibody. Antigen retrieval was carried-out by incubating sections in sodium citrate buffer (10 mM, pH 6.0) in a microwave oven at 750 Watts for 5 minutes. The sections were then rinsed in 3% hydrogen peroxide(Drug information on hydrogen peroxide) to block endogenous peroxidase and incubated for 1 hour at room temperature with either of the following primary antibodies: a goat polycolonal ICAM-1 (CD54) antibody from R&D Systems (R&D Systems, Inc., Minneapolis, MN) or a monoclonal antibody against the Platelet Adhesion Molecule (PECAM) (CD31) from Dako (DakoCytomation California, Inc., Carpinteria, CA). Staining was visualized using the avidin-biotin peroxidase complex (Vectastain ABC kit, Vector Laboratories, Burlingame, CA) and the 3,3'-diaminobenzidine tetrahydrochloride (Sigma-Aldrich, St. Louis, MI) chromogen substrate. Light hematoxylin stain was used for nuclear counterstaining. Negative controls for each tissue section consisted of substituting the corresponding pre-immune serum for the primary antibody.

Assessment of immunohistochemical (IHC) staining and statistical analysis
Intensity of ICAM-1 staining was evaluated using a semi-quantitative 4-point rating method with the following scoring system: 0, absence of staining; 1, light staining; 2 moderate staining; and 3, strong staining. Each of these possible scores was established in advance of rating the fields via reference to external stained specimens unrelated to this study. In order to determine inter-rater reliability of this scale, two independent judges scored a series of 35 separate fields on slides from 4 separate patient samples. The degree of concordance was then assessed by use of Cohen's kappa statistic, which yielded a value of 0.67, indicating a high degree of agreement between the judges.

Non-parametric statistical analysis was performed by the Mann-Whitney Rank Sum Test with p < 0.05 considered significant.

Results
Figure 1 (C-F) displays IHC staining for ICAM-1 in endometrial specimens obtained across the menstrual cycle. As expected, there was a lack of staining in the negative control (A). The endothelium of all specimens examined stained prominently, displaying an intensity that appeared to be independent of hormonal or inflammatory state. Thus, staining intensity did not vary significantly among specimens obtained from the estrogen-regulated follicular phase (C), the progestin-dominated luteal phase (D), or from the pro-inflammatory milieu characteristic of the ovarian steroid withdrawal-initiated menstrual phase (E-F). In both intensity and specificity for the endothelium, immunostaining for ICAM-1 was similar to that of CD31 (shown in Figure 1B ), a documented endothelial cell marker whose expression was demonstrated by Tawia [18] to be essentially unchanged across the menstrual cycle. The "stromal ball" displayed by the specimen of menstrual endometrium in (F) indicates that in contrast with the intense IHC staining for ICAM-1 exhibited by the endothelium of the compressed vessels, the stromal cells demonstrate at most only weakly positive immunoreactivity. This observation contradicts a report that stromal cells of cycling human endometrium display significant ICAM-1 IHC staining whose intensity peaks during the menstrual phase [18].
 

Figure 1
Immunostaining for ICAM-1 and CD 31 in human endometrium during the menstrual cycle.

Figure 2 displays IHC staining for ICAM-1 in endometrial specimens obtained after administration of the LTPOCs, Norplant (B-E) and Mirena (F-I). As observed in Figure 1 for endometria obtained across the menstrual cycle, Figure 2 demonstrates that imunoreactive ICAM-1 was also localized specifically to the endothelium of LTPOC-derived endometrium with staining intensity that was equivalent among various vessel types and independent of both steroidal and inflammatory state. Thus, consistent with direct delivery of LNG to the uterus with Mirena contraception the progestin-induced decidualization reaction in these specimens (F-I) is much greater than in Norplant-derived specimens (B-E). Moreover, despite the documented increase in pro-inflammatory cytokines[6,7] and leukocyte infiltration [8,9] during LTPOC-induced abnormal uterine bleeding, no differences in endothelial cell IHC staining for ICAM-1 were evident whether the endometrium exhibited abnormal uterine bleeding or gave no indication of bleeding. Specifically, with Norplant administration this comparison was between bleeding (C, E) and non-bleeding sites (B, D) of the same endometrium. With Mirena administration comparisons are between patients experiencing abnormal uterine bleeding G, I) and those who were not bleeding (F, H). For both figures, our rating of staining intensity was characterized by good inter-rater reliability, with a Cohen's kappa value of 0.67 for observations made by two independent observers (See Methods for details).
 

Figure 2
Immunostaining for ICAM-1 in human endometrium during long term only contraceptive (LTPOC) administration

 

Discussion
The current study found that human endometrial endothelial cells displayed prominent IHC staining for ICAM-1 in specimens obtained from the follicular, luteal and menstrual phases, and after administration of the LTPOCs, Norplant (subdermal LNG) and Mirena (intrauterine LNG) and that this staining was of equivalent intensity in all vessels examined. By contrast, the glands exhibited virtually no immunostaining and the stromal cells only weak immunoreactivity. Although IHC staining for ICAM-1 was previously demonstrated in the endometrial endothelium of specimens obtained across the menstrual cycle [17-19], two of the reports found significant ICAM-1 staining in the stromal cells [18,19], with one study noting that ICAM-1 levels in both stromal cells and endothelial cells were elevated in menstrual endometrium compared with specimens examined earlier in the menstrual cycle [18].

The demonstration in the current study that ICAM-1 levels are equivalent in the endometrial endothelium of specimens from the E2-dominated follicular phase, the progesterone(Drug information on progesterone)-exposed luteal phase, and the steroid-withdrawal-initiated menstrual phase suggests that ICAM-1 expression is not under direct ovarian steroid regulation. This conclusion was supported by the ICAM-1 immunostaining results obtained in endometrial biopsies during use of subdermal and intrauterine LNG (Norplant and Mirena respectively) contraception. That both LTPOCs produce a hyperprogestational endometrial milieu is suggested by the observation of significantly high endometrial levels of the progesterone receptor (PR) isoforms PRA and PRB after administration of Norplant [24] as well as the injectable LTPOC, Provera [23], whereas PRA appears to mediate the long-term effects of LNG in the endometrium during intrauterine LNG contraception [6]. Endometrial levels of LNG that are 1000 times greater with intrauterine delivery (Mirena) than with subdermal LNG administration (Norplant) [28]. However, the current study observed no difference in endometrial endothelial ICAM-1 immunostaining regardless of which LNG formulation was evaluated.

Evidence presented in the current study also argues against a role for the local inflammatory milieu in regulating endothelial cell expressed ICAM-1. Thus, equivalent immunostaining intensity was observed when follicular and luteal phase endometria were compared with menstrual, Norplant, and Mirena-derived endometria, which undergo a marked leukocyte infiltration [3-5,8,9] and exhibit other local pro-inflammatory changes such as a high prostaglandin-generating capacity and elevated interleukin-8 (IL-8) levels [1,2,6,7].

ICAM-1 is both constitutively expressed and transcriptionally regulated on the surface of several cell types [29]. Consistent with the latter, the ICAM-1 gene promoter contains several cis-acting elements that predict responsiveness to pro-inflammatory cytokines and reactive oxygen species (ROS). Cooperativity between transcription factors C/EBP and NfκB mediate tumor necrosis factor alpha (TNF-α) and interleukin 1beta (IL-1β) responses. Actions of H2O2 are mediated by antioxidant response elements (ARE), which bind transcription factors AP-1 and Ets [29]. As expected, TNF-α, whose pro-inflammatory activity requires ROS formation, induces ICAM-1 expression in endothelial and epithelial cells and H2O2 induces ICAM-1 expression in endothelial cells. However, H2O2 does not affect ICAM-1 expression in epithelial cells [30].

In vivo studies have generally relied on IHC to localize and assess ICAM-1 levels. Table 1 summarizes the results of nine previous reports, three in nonpregnant endometrium [17-19] and six in pregnant endometrium (decidua) [31-36]. The majority of these agree with the current results, by observing intense ICAM-1 immunostaining in a variety of blood vessel types that appears to be constitutive even in a pro-inflammatory milieu. Recently, in first trimester from cases of hemorrhagic, acutely inflamed, regressing deciduas, we found that endothelial cell ICAM-1 staining intensity was unaffected by the proximity of blood vessels to cytokine-expressing neutrophils [36]. Moreover, despite reports that preeclamptic decidua display a marked macrophage infiltrate and high levels of TNF-α, [37,38] other reports [34,35] found that endothelial cell ICAM-1 expression was similar in decidua from preeclamptic or gestationally age-matched placentas. These studies agree with observations made in the current study for nonpregnant endometrium. It found equivalent ICAM-1 immmunostaining intensity in the endothelium of follicular and luteal phase endometria compared with menstrual, Norplant and Mirena-derived endometria, which exhibit such local pro-inflammatory changes as a marked leukocyte infiltrate [3-5,8,9], high prostaglandin-generating capacity and elevated interleukin-8 (IL-8) levels [1,2,6,7].
 

Table 1
Previously reported ICAM-1 immunostaining in non-pregnant and gestational endometrium. FT: first trimester; FF-PE: formalin-fixed, paraffin-embedded; PE: pre-eclampsia, IUGR: intrauterine growth retardation

Regulation of neutrophil migration into inflammatory sites reflects interactions between the IL-8 chemokine and the ICAM-1 adhesion molecule. The former establishes a chemotactic gradient that promotes neutrophil trafficking from the circulation towards the endothelium [39]. This enables the latter to mediate neutrophil rolling and adhesion prior to transendothelial migration [40]. Neutrophils are rich source of gelatinase B (MMP-9) [41], which degrades basement membrane associated collagens IV and V [42]. Moreover, neutrophil-derived MMP-9 cleaves IL-8 to a truncated form [IL-8(7-77)] with 10–30- fold greater potency in promoting neutrophil activation and chemotaxis [41]. The onset of AUB during LTPOC administration stems from fragile, abnormally distended vessels with impaired basement membranes"[43,44]. Administration of LTPOCs produces local hypoxia stemming from reduced uterine vasomotion (45), and increases stromal cell expression of tissue factor, which can generate thrombin at local sites of AUB [46]. The demonstration in the current study that ICAM-1 is constitutively expressed by the endometrial endothelium highlights the important role that altered IL-8 expression plays in regulating neutrophil trafficking into the endometrium. Toward that end, we recently demonstrated that IL-8 expression is enhanced by hypoxia and thrombin in stromal cells derived from pre-decidualized human endometrium [47].

Conclusion
In the context of our current observations, constitutive endothelial ICAM-1 expression alone cannot account for the marked neutrophil infiltration that characterizes both premenstrual human endometrium as well as the endometrium resulting from LTPOC therapy.

Authors' contributions
FS designed the study and drafted the manuscript. GK conducted immunohistochemical procedures. RNB assessed immunohistochemical staining. HC performed clinical assessment and collection of specimens related to LTPOC treatment. EK performed the statistical analyses and critically reviewed the manuscript. CJL participated in the conception of the study and critically reviewed the manuscript. All authors read and approved the final manuscript.

Acknowledgements
This work was supported by a grant from the National Institutes of Health 5 RO1 HD033937-06 (CJL).

 

Table 1
 
Previously reported ICAM-1 immunostaining in non-pregnant and gestational endometrium. FT: first trimester; FF-PE: formalin-fixed, paraffin-embedded; PE: pre-eclampsia, IUGR: intrauterine growth retardation
 
Reference
 
Tissue type
 
Tissue Preparation
 
Endothelial Cell ICAM-1 staining
 
Non-endothelial Cell ICAM-1 staining
 

17
 
Cycling endometrium
 
Frozen (formalin-fix)
 
Strong, constitutive
 
Uniform staining of glands, stroma, and epithelium; strong lymphoid staining
 
18
 
Cycling endometrium
 
Frozen (formalin-fix)
 
Strong but variable among vessel types with peak at menstrual
 
Glandular and luminal epithelium negative, stroma weak in proliferative/secretory phases but strong at menstrual
 
19
 
Cycling endometrium
 
Frozen (acetone-fix) and FF-PE
 
Strong throughout entire cycle
 
Glandular and luminal epithelium variable, stroma stained throughout cycle with increase expression in menstrual; widespread lymphoid staining
 
31
 
FT Decidua
 
Frozen (acetone-fix)
 
Strong in all vessel types
 
Glands negative, stroma weak, moderate staining of lymphocytes
 
32
 
FT Decidua, placenta
 
Frozen (acetone-fix)
 
Strong in all vessel types
 
Stroma negative, strong lymphocyte staining, strong staining of decidua parietalis,
 
33
 
FT decidua
 
Frozen (acetone-fix)
 
Strong in all vessel types
 
Glands negative, some stroma positive
 
34
 
Decidua, placental bed
 
Frozen (acetone-fix)
 
Strong, unchanged in normal vs. PE, IUGR, or PE+IUGR
 
Weak scattered stromal cell staining
 
35
 
Decidua, placenta
 
Frozen (acetone-fix)
 
Strong, unchanged in normal vs. PE
 
Villous trophoblasts negative, <10% interstitial trophoblasts stained
 
36
 
FT decidua
 
FF-PE
 
Strong in all vessel types, same in normal vs. inflammation; constitutive
 
Glands negative, stroma weak
 

 

 

Figure 1

 

Immunostaining for ICAM-1 and CD 31 in human endometrium during the menstrual cycle.  Negative control for menstrual endometrium (A). Prominent ICAM-1 staining is evident in the endothelium in endometrial specimens from the follicular phase (C), luteal phase (D), and menstrual phase (E, F). Similar endothelial cell staining intensity and specificity for CD 31 is seen in the menstrual specimen shown in (B). The prominent structure in the menstrual specimen shown in (F) is a "stromal ball," which results from degenerative changes of the stroma. Note the compressed blood vessels displaying prominent immunostaining for ICAM-1, whereas the surrounding stromal cells were only weakly positive. Arrow = blood vessel; g = gland. Bar = 50 μm.

 

Figure 2

 

Immunostaining for ICAM-1 in human endometrium during long term only contraceptive (LTPOC) administration. IHC staining in the endothelium was prominent and specific for the endothelium in in all endometrial specimens examined. Samples obtained from women using Norplant (subdermal LNG) (B-E)-: (B) 3 months post-Norplant non-bleeding site; (C) 3 months post-Norplant, bleeding site; (D) 12 months post-Norplant, non-bleeding site; and (E) 12 months post Norplant, bleeding site. Similar results were seen in endometrial specimens from women using Mirena (intrauterine LNG) (F-I):-;(F) 3 months post-Mirena, non-bleeding (F); 3 months post-Mirena, bleeding; (G) 12 months post-Mirena, non-bleeding; and (I) 12 months post-Mirena, bleeding. Note that the stromal cells exhibit a much greater decidualization reaction following intrauterine administration of LNG (F-I) than after subdermal LNG (B-E). Arrow = blood vessel; g = gland; DC = decidualized stromal cell. Bar = 50 μm.

 

 

 

Join the Conversation

Want to join the conversation? Just sign in or register today to become part of our growing, online community.





References
1. Critchley HO, Jones RL, Lea RG, Drudy TA, Kelly RW, Williams AR, Baird DT: Role of inflammatory mediators in human endometrium during progesterone withdrawal and early pregnancy. J Clin Endocrinol Metab 1999, 84(1):240-248. [PubMed Abstract] [Publisher Full Text]
2. Baird DT, Cameron ST, Critchley HOD, Drudy TA, Howe A, Jones RL, Lea RG, Kelly RW: Prostaglandins and menstruation. Eur J Obstet Gynecol Rep Biol 1996, 7:15-17. [Publisher Full Text]
3. Starkey PM, Clover LM, Rees MCP: Variation during the menstrual cycle of immune cell populations in human endometrium. Eur J Obstet Gynecol Reprod Biol 1991, 39:203-207. [PubMed Abstract] [Publisher Full Text]
4. Bulmer JN, Morrison L, Longfellow M, Ritson A, Pace D: Granulated lymphocytes in human endometrium: histochemical and immunohistochemical studies. Hum Repro 1991, 6:791-798.
5. Salamonsen LA, Wooley DE: Menstruation: induction by matrix metalloproteinases and inflammatory cells. J of Repro Immunol 1999, 44:1-27. [Publisher Full Text]
6. Critchley HOD, Wang H, Kelly RW, Gebbie AE, Glasier AF: Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgesterel-releasing intra-uterine system. Hum Reprod 1998, 3:11210-1217.
7. Jones RL, Critchley HO: Morphological and functional changes in human endometrium following intrauterine levonorgestrel delivery. Hum Reprod 2000, 15(Suppl 3):162-172. [PubMed Abstract]
8. Vincent AJ, Malakooti N, Zhang J, Rogers PA, Affandi B, Salamonsen LA: Endometrial breakdown in women using Norplant is associated with migratory cells expressing matrix metaloproteinase-9 (gelatinase B). Hum Reprod 1999, 14:807-815. [PubMed Abstract] [Publisher Full Text]
9. Critchley HO, Wang H, Jones RL, Kelly RW, Drudy TA, Gebbie AE, Buckley CH, McNeilly AS, Glasier AF: Morphological and functional features of endometrial decidualization following long-term intrauterine levonorgestrel delivery. Hum Reprod 1998, 13(5):1218-1224. [PubMed Abstract] [Publisher Full Text]
10. Springer TA: Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994, 76:301-314. [PubMed Abstract] [Publisher Full Text]
11. Wang Q, Doerschuk CM: The signaling pathways induced by neutrophil-endothelial cell adhesion. Antioxid Redox Signal 2002, 4(1):39-47. [PubMed Abstract] [Publisher Full Text]
12. Greenwood J, Etienne-Manneville S, Adamson P, Couraud PO: Lymphocyte migration into the central nervous system: implication of ICAM-1 signaling at the blood-brain barrier. Vascul Pharmacol 2002, 38(6):315-322. [PubMed Abstract] [Publisher Full Text]
13. Nishibori M, Takahashi HK, Mori S: The regulation of ICAM-1 and LFA-1 interaction by autacoids and statins: a novel strategy for controlling inflammation and immune responses. J Pharmacol Sci 2003, 92(1):7-12. [PubMed Abstract] [Publisher Full Text]
14. Ren G, Dewald O, Frangogiannis NG: Inflammatory mechanisms in myocardial infarction. Curr Drug Targets Inflamm Allergy 2003, 2(3):242-256. [PubMed Abstract] [Publisher Full Text]
15. Hayflick JS, Kilgannon P, Gallatin WM: The intercellular adhesion molecule (ICAM) family of proteins. New members and novel functions. Immunol Res 1998, 17(3):313-327. [PubMed Abstract] Review
16. Sligh \surJE Jr, Ballantyne CM, Rich SS, Hawkins HK, Smith CW, Bradley A, Beaudet AL: Inflammatory and immune responses are impaired in mice deficient in intercellular adhesion molecule 1. Proc Natl Acad Sci U S A 1993, 90(18):8529-8533. [PubMed Abstract] [Publisher Full Text] [PubMed Central Full Text]
17. Tabibzadeh SS, Poubourdis D: Expression of leukocyte adhesion molecules in human endometrium. Amer J Clin Pathol 1990, 93:183-189.
18. Tawia SA, Beaton LA, Rogers PAW: Immunolocalization of the cellular adhesion molecules, intercellular adhesion molecule-1 (ICAM-1) and platelet adhsion molecule (PECAM), in human endometrium throughout the menstrual cycle. Hum Reprod 1993, 8:175-181. [PubMed Abstract]
19. Thomson AJ, Greer MR, Young A, Boswell F, Telfer JF, Cameron IT, Norman JE, Campbell S: Expression of intercellular adhesion molecules ICAM-1 and ICAM-2 in human endometrium throughout the menstrual cycle. Mol Hum Reprod 1999, 5(1):64-70. [PubMed Abstract] [Publisher Full Text]
20. Shulnan LP, Nelson AL, Darney PD: Recent developments in hormone delivery systems. Am J Obstet Gynecol 2004, 190(4 Suppl):S39-48. [PubMed Abstract] [Publisher Full Text]
21. McGavigan CJ, Cameron I: The Mirena levonorgestrel system. Drugs Today (Barc) 2003, 39(12):973-984. [PubMed Abstract] [Publisher Full Text]
22. Critchley HO: Endometrial effects of progestogens. Gyn Forum 2003, 8:6-10.
23. Hickey M, Simbar M, Markham R, Young L, Manconi F, Russell P, Fraser IS: Changes in vascular basement membrane in the endometrium of Norplant users. Hum Reprod 1999, 14(3):716-721. [PubMed Abstract] [Publisher Full Text]
24. Lockwood CJ, Runic R, Wan L, Demopoulos R, Schatz F: The role of tissue factor in regulating endometrial hemostasis: implications for progestin-only contraception. Hum Reprod 2000, 15:144-151. [PubMed Abstract]
25. Runic R, Schatz F, Wan L, Demopoulos R, Krikun G, Lockwood CJ: Effects of norplant on endometrial tissue factor expression and blood vessel structure. J Clin Endocrinol Metab 2000, 85:3853-3859. [PubMed Abstract] [Publisher Full Text]
26. Rogers PA: Endometrial vasculature in Norplant users. Hum Reprod 1996, 11(Suppl 2):45-50. [PubMed Abstract]
27. Noyes RW, Hertig AT, Rock J: Dating the endometrial biopsy. Fertil Steril 1950, 1:3-25.
28. Pekonen F, Nyman T, Lahteenmaki P, Haukkamaa M, Rutanen EM: Intrauterine progestin induces continuous insulin-like growth factor- binding protein-1 production in the human endometrium. J Clin Endocrinol Metab 1992, 75:660-664. [PubMed Abstract] [Publisher Full Text]
29. Roebuck KA, Finnegan A: Regulation of intercellular adhesion molecule-1 (CD54) gene expression. (Review). J Leukoc Biol 1999, 66(6):876-888. [PubMed Abstract] [Publisher Full Text]
30. Roebuck KA: Oxidative stress regulation of IL-8 and ICAM-1 gene expression:differential activation and binding of the transcription factors AP-1 and NF kappa B. (Review). Int J Mol Med 1999, 3:223-230.
31. Marzusch K, Ruck P, Geiselhart A, Handgretinger R, Dietl JA, Kaiserling E, Horny HP, Vince G, Redman CW: Distribution of cell adhesion molecules on CD56++, CD3-, CD16- large granular lymphocytes and endothelial cells in first-trimester human decidua. Hum Reprod 1993, 8(8):1203-1208. [PubMed Abstract]
32. Burrows TD, King A, Loke YW: Expression of adhesion molecules by endovascular trophoblast and decidual endothelial cells: implications for vascular invasion during implantation. Placenta 1994, 15(1):21-33. [PubMed Abstract]
33. Ruck P, Marzusch K, Kaiserling E, Horny HP, Dietl J, Geiselhart A, Handgretinger R, Redman CW: Distribution of cell adhesion molecules in decidua of early human pregnancy. An immunohistochemical study. Lab Invest 1994, 71(1):94-101. [PubMed Abstract]
34. Lyall F, Greer IA, Boswell F, Young A, Macara LM, Jeffers MD: Expression of cell adhesion molecules in placentae from pregnancies complicated by pre-eclampsia and intrauterine growth retardation. Placenta 1995, 16(7):579-587. [PubMed Abstract] [Publisher Full Text]
35. Jaakkola K, Jokimaa V, Kallajoki M, Jalkanen S, Ekholm E: Pre-eclampsia does not change the adhesion molecule status in the placental bed. Placenta 2000, 21(2–3):133-141. [PubMed Abstract] [Publisher Full Text]
36. Lockwood CJ, Paidas M, Krikun G, Koopman LA, Masch R, Kuczynski E, Kliman H, Baergen RN, Schatz F: Inflammatory cytokine and thrombin regulation of interleukin-8 and intercellular adhesion molecule-1 expression in first trimester human decidua. J Clin Endocrinol Metab 2005, 90(8):4710-4715. [PubMed Abstract] [Publisher Full Text]
37. Lockwood CJ, Matta P, Krikun G, Koopman LA, Masch R, Toti P, Arcuri F, Huang ST-J, Funai EF, Schatz F: Regulation of monocyte chemoattractant protein-1 expression by tumor necrosis factor alpha and interleukin 1 beta in first trimester human decidual cells: implications for preeclampsia. Am J Pathol, in press.
38. Reister F, Frank HG, Kingdom JC, Heyl W, Kaufmann P, Rath W, Huppertz B: Macrophage-induced apoptosis limits endovascular trophoblast invasion in the uterine wall of preeclamptic women. Lab Invest 2001, 81(8):1143-1152. [PubMed Abstract]
39. Springer TA: Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994, 76:301-314. [PubMed Abstract] [Publisher Full Text]
40. Issekutz AC, Rowter D, Springer TA: Role of ICAM-1 and ICAM-2 and alternate CD11/CD18 ligands in neutrophil transendothelial migration. J Leukoc Biol 1999, 65(1):117-126. [PubMed Abstract] [Publisher Full Text]
41. Van den Steen PE, Proost P, Wuyts A, Van Damme J, Opdenakker G: Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood 2000, 96(8):2673-2681. [PubMed Abstract] [Publisher Full Text]
42. Vu TH, Werb Z: Gelatinase B: Structure, regulation, and function. In Matrix Metalloproteinases.. Edited by: Parks WC and Mecham RP. San Diego: Academic Press; 1998:115-148.
43. Hickey M, Simbar M, Markham R, Young L, Manconi F, Russell P, Fraser IS: Changes in vascular basement membrane in the endometrium of Norplant users. Hum Reprod 1999, 14(3):716-721. [PubMed Abstract] [Publisher Full Text]
44. Simbar M, Manconi F, Markham R, Hickey M, Fraser IS: A three-dimensional study of endometrial microvessels in women using the contraceptive subdermal levonorgestrel implant system, norplant. Micron 2004, 35(7):589-595. [PubMed Abstract] [Publisher Full Text]
45. Hickey M, Carati C, Manconi F, Gannon BJ, Dwarte D, Fraser IS: The measurement of endometrial perfusion in norplant users: a pilot study. Hum Reprod 2000, 15(5):1086-1091. [PubMed Abstract] [Publisher Full Text]
46. Runic R, Schatz F, Wan L, Demopoulos R, Krikun G, Lockwood CJ: Effects of norplant on endometrial tissue factor expression and blood vessel structure. J Clin Endocrinol Metab 2000, 85(10):3853-3859. [PubMed Abstract] [Publisher Full Text]
47. Lockwood CJ, Kumar P, Krikun G, Kadner S, Dubon P, Critchley H, Schatz F: Effects of thrombin, hypoxia, and steroids on interleukin-8 expression in decidualized human endometrial stromal cells: implications for long-term progestin-only contraceptive-induced bleeding. J Clin Endocrinol Metab 2004, 89(3):1467-1475. [PubMed Abstract] [Publisher Full Text]

Reproductive Biology and Endocrinology 2006, 4:2 doi:10.1186/1477-7827-4-2

The electronic version of this article is the complete one and can be found online at: http://www.rbej.com/content/4/1/2
© 2006 Schatz et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


TopicIndex

 

Adhesions
Breast Health and Breast Care
Contraception
Electronic Health Records (EHRs)
Endometriosis
Fetal Monitoring
Fibroids
Gestational Diabetes
Gynecologic Oncology
Hysterectomy
Infertility
In Vitro Fertilization (IVF)
Laparoscopy
Malpractice

  Menopause
Osteoporosis

Polycystic Ovary Syndrome
Postpartum Depression
Pelvic Pain
Premenstrual Syndrome/Premenstrual Dysphoric Disorder (PMS/PMDD)
Pregnancy and Birth
Sex-related Issues
Ultrasound
Urogynecology
Uterine (Endometrial) Polyps
Weight Management
Young Women

 

MedicaForums

The Plan B Debacle Continues
Medica Forums - 6/17/13
First, Plan B was only available OTC to women age 17 and up. In April, a judge ordered that it be made available to women of all ages. Now, an appeals court judge has stayed an order that would make a one-dose version of the emergency contraception available to all ages, while allowing the two-dose drug to be sold OTC without restriction. What do you make of all this?
muscle pain relief in Hong Kong
Medica Forums - 6/15/13
muscle pain relief in Hong kong
eToims is a non-invasive pain therapy treatment for individuals desiring general physical health maintenance and enhancement or relief from chronic pain.Back pain is often caused or aggravated by bad or worn-out mattresses. A new pressure-relieving mattress and pillow can make a huge difference. It can support your back, shoulders and neck where it needs it most and thereby help you sleep in a better position, relieving pressure points and back pain. For more information on pressure relieving mattresses and pillows click here.For more information visit us at- Email-info@etoims.com,Contact- +1 215-387-0550.
Whatever Happened To OB-GYN-L?
Medica Forums - 6/12/13
For the past few months, I have not received any posts on the listserv OB-GYN-L. I would get daily posts in my e-mail. Where has it gone, what has happened to it? What can I do to get back on the list?

If anybody has any information, send me a note at:

dean@thehuffpeople.net


Dean Huffman
Pregnancy categories of drugs
Medica Forums - 6/6/13
Pregnant woman and the newborn infant in breast feeding both of them need safety. So, caution in use of drugs in pregnancy and during lactation is mandatory. The knowledge of risk-benefit ratio of different drugs should be in mind of the doctor while prescribing a pregnant or lactating lady.Definitions of Pregnancy categories of drugs and a table showing pregnancy categories of drugs and safety of drugs in lactation are given here.

Definitions of Pregnancy categories of drugs:

On the basis of the potentiality for producing birth defects drugs in pregnancy are grouped into 1 of 5 categories which are A,B, C, D and X. Drugs of class A and B are considered safe and can be used routinely.

Pregnancy Category A : Controlled studies in pregnant women fail to detect risk to the fetus in the first trimester and no evidence of risk in later trimesters. The possibility of harm to the fetus appears remote by using the drugs of pregnancy category A.

Pregnancy Category B : Presumed safety on the basis of animal studies, with no controlled study in pregnant women, or animal studies have shown an adverse effect which was not confirmed in controlled studies in women in the first trimester and there is no evidence of risk to the fetus in later trimesters.

Pregnancy Category C : Studies in women and animals are not available or studies in animals have shown adverse effects on the fetus and there is no controlled study in women. Drugs should be given in pregnancy only if the potential benefits justify the potential risk to the fetus.

Pregnancy Category D : There is positive evidence of risk to the human fetus (unsafe), however in a life-threatening illness the potential risk may be justified if there are no other alternatives.

Pregnancy Category X : Highly unsafe: risk of use outweighs any potential benefit. Drugs in this category are contraindicated in pregnant women or in a woman who may become pregnant. To get more please visit -
http://medicalforall.net/drugs-pregnancy-lactation/
Attendance in L and D
Medica Forums - 6/1/13
Recently, I had the occasion to review a case of a term primigravida with PROM in a private hospital (no housestaff or in house obstetricians). She was seen by an obstetrician soon after arrival, evaluated, and pitocin induction begun.

She did not deliver for around 29 hours after admission, and the delivering obstetrician (a different physician) was physically present during the last 2 hours of labor prior to delivery.

Simply put, while the two involved obstetricians were in communication by phone with the nursing staff throughout labor (separately as their "shifts" did not overlap), no one actually came to the bedside and wrote a note) from admission until around 2 hours before delivery.

Medical staff bylaws call for a daily progress note; this bylaw was easily met.

In reviewing the case, it did not "feel good" that no one came to the bedside.

My questions:

1. Does anyone have or know of any guidelines to mandate such bedside attendance? Of course, we all hope that the involved physicians would not need said guidelines.
2. Does anyone have a suggestion of hospital/nursing protocols? Simply, in this case I would like to have had a charge nurse or bedside nurse simply say, "Hey, no one has been by for a while. What's up?"

Garry
“A weekly online journal dedicated to original and innovative research".
Medica Forums - 6/1/13
Reviews Of Progress is a weekly peer-reviewed scientific journal that covers original research and reviews. It publishes all articles under the guidance of the editorial team. The current Editor-in-Chief is Pindipol S.I, the editorial office is in Solapur.
Retained Placenta (Ronald Ainsworth – February 2013)
Medica Forums - 5/27/13
I helped another physician with removal of a retained placenta last night, we were unsuccessful in removing it vaginally, her cervix was too closed to allow manual removal and we could only get a few pieces out with ring forceps and a large curette, so we did a laparotomy/hysterotomy and were able to preserve the uterus. The placenta turned out not to be an accreta and it was easily removed via that route through a low vertical incision on the uterus. Any thoughts on the appropriate CPT code would be appreciated. The patient came in through the ER five days after home delivery by her husband. She was severely anemic, rcvd 7 units of blood and is still quite ill and in the ICU but improving.

Ronald E. Ainsworth, MD, FACOG
App to compute fetal weight percentiles
Medica Forums - 5/23/13
Hello,

Has anyone tried FetalGrowth app (App Store for iPhone/iPad) ? I'm interested in using a simple and handy tool to calculate fetal percentiles, and I came across this app, which seems it does the job (plots growth charts, as well). I haven't seen anything else, besides this app, so I was wondering if there are people who have already tried it.

Thanks !
Atypical endometrial cells
Medica Forums - 5/19/13
Had a case the other day with the above finding on a pap. She was age 36 and had a Mirena in place. How do people feel about the idea of trying to do an EMB with an IUD in place? If not, how do we proceed?
Welcome to the new ObGyn.net Forum!
Medica Forums - 5/12/13
Welcome to the new ObGyn.net Forum!

To all the members of OB-GYN-L… Thank you for coming! I’m thrilled that you’ve decided to check out the new Forum site, and look forward to reading about what’s on your mind.

If you’re new to the ObGyn.net community... welcome aboard! You’ve just joined an outstanding group of physicians and health care professionals who have been sharing information, answering questions, and building professional relationships via the site’s listserv for nearly 20 years.

Feel free to poke around on the site to get a feel for things, or take a look at the Help Topics page for instructions on how to use the different features of the site.

A few quick tips:
For those of you who like getting new Forum messages delivered directly to your inbox, the first thing you’ll want to do is click on the ‘Follow this forum’ button on the main page. You’ll have the option of getting notifications immediately, as a daily digest, a weekly digest, or only when you’re not online (which is to say, if you’re on the site when someone posts a message, you won’t be notified of it). You won’t be able to post on the site just by replying to the email, but the message will contain a link that takes you directly to the message you’d like to reply to.

You can also follow individual conversations without following the whole list by going into the topic and clicking the ‘Follow this topic’ button next to the title.

Also, in ‘My Profile’ you can:
  • Enter your professional information, including specialty, subspecialty, and education (by clicking ‘Edit my profile’)
  • See your activity on the Forum, such as what discussions you have initiated or replied to, content you’ve ‘liked,’ and activity of people you’ve made your friends
In ‘My Settings’ you can:
  • Add or change your photo
  • Edit your birthday, gender, interests, location
  • Create a signature for your posts
  • Change the types of content you get notifications for, or change the way you receive notifications
If you have questions, feel free to respond to this post or send me a direct message by clicking on the envelope icon.

Happy posting!

EducationalTutorials


Educational Tutorial: Complications of Laparoscopy
February 7, 2012

There are a variety of complications that can occur during laparoscopic surgery. In this tutorial learn some of the complications and tips to avoid them.

Educational Tutorial: Low Molecular Weight Heparin in Recurrent Abortions
January 17, 2012

Review information on low molecular weight heparin in recurrent miscarriages in this educational tutorial.

Laparoscopy in Infertility An Evidence Based View
October 14, 2011

Thromboembolic Disease in Pregnancy and Puerperium
September 14, 2011

CaseStudies


Fetal Abdomen with Gallbladder Calculi
Dr. Muktachand and Dr. Trupti , September 27, 2011

B mode and 3D Ultrasound images of a fetal abdomen (35wks) revealing gallbladder calculi

Sacrococcygeal Teratoma?
Dr. Jaydeep , September 14, 2011

This case study shows a 26 week gestation with a cystic mass close to the sacrum.

Fetal Cardiac Anomalies
Joshua Abbott Copel, MD OBGYN.net Advisory Board Member , July 19, 2011

CC is a 31 year old primigravida who was referred for ultrasound at a community hospital due to suspected cardiac anomalies noted on a screening sonogram at her doctor's office. Due to concern about a probable cardiac abnormality an amniocentesis was performed at the local hospital.

Single Umbilical Artery Color Doppler
Abana Cerekja , June 15, 2011

Single umbilical artery color doppler, transverse scan of urinary bladder shows single umbilical artery (left), transverse section of umbilical cord showing only two vessels: one vein and one artery (right).

Ductus Venosus Spectral Waveform
Dr. Joe Antony , June 15, 2011

Normal 35 week pregnancy

FromPhysiciansPractice

Key Differences between FQHCs and RHCs
Chastity Werner, RHIT, June 13, 2013
FQHCs and RHCs take up a unique niche among physician practices. And that affects compensation and billing.
Improving Care Coordination in Your Practice
Susanne Madden,  June 12, 2013
Practices are feverishly working to control the rising costs of healthcare - effective care coordination can help.
Refunding Overpayments: Two Options for Medical Practices
Ericka L. Adler,  June 12, 2013
Medicare and Medicaid providers must return overpayments once identified. Here are two different refund approaches for practices to consider when necessary.
Four Easy Ways to Boost Patient Time of Service Collections
Aubrey Westgate,  June 12, 2013
Simple ways your medical practice staff can increase the likelihood patients will pay when presenting for appointments.
iPad Alternatives for Mobile Physicians
Marisa Torrieri, June 11, 2013
As more physicians are seeing the merits of media tablets, the market is expanding, too.
 

 

  • On This Site
  • Most Emailed
  • On This Topic

MostPopular

  • The Relationship Between Placental Location and Fetal Gender (Ramzi’s Method)

    JUN 14 2011 OBGYN.NET READ >>

  • Daily Dx: Middle-Aged Woman with Non-specific Pelvic Pain

    JUN 4 2013 OBGYN.NET READ >>

  • Daily Dx: Three-Vessel View of a Fetal Heart

    MAY 28 2013 OBGYN.NET READ >>

  • Daily Dx: A Child with Dysuria and Pelvic Pain

    JUN 11 2013 OBGYN.NET READ >>

  • The Best Screening Strategies for Cervical Cancer

    JUN 7 2013 OBGYN.NET READ >>

MostPopular

  • FDA Warning: Don’t Use Magnesium Sulfate to Stop Pre-term Labor

    JUN 6 2013OBGYN.NET READ >>

  • In Vitro Fertilization Increases Risk of Embolism

    JUN 3 2013OBGYN.NET READ >>

  • The Best Screening Strategies for Cervical Cancer

    JUN 7 2013OBGYN.NET READ >>

  • Nitrofurantoin is Low-Risk in Pregnancy

    MAY 27 2013OBGYN.NET READ >>

  • Thrombophilia and Adverse Pregnancy Outcomes

    AUG 17 2011OBGYN.NET READ >>

MostPopular

  • STD and IUD for Adolescent Contraception

    AUG 3 2011 OBGYN.NET READ >>

  • Contraception

    AUG 3 2011 OBGYN.NET READ >>

  • Emergency Contraception (Evidence Based)

    AUG 3 2011 OBGYN.NET READ >>

  • Emergency contraception

    AUG 3 2011 OBGYN.NET READ >>

  • Ob/Gyns Should Offer Long Acting Reversible Contraception First to Lower Unintended Pregnancy Rates

    MAY 9 2013 OBGYN.NET READ >>

 

 

 

SearchMedicaSearchResult

Find peer-reviewed literature and websites for practicing medical professionals

CME on Contraception
Evidence on Contraception
Guidelines on Contraception
Patient Education on Contraception
Clinical Trials on Contraception
Practical Articles on Contraception
Research and Reviews on Contraception
All "Contraception" results

EventCalendar

  • The 5th IVI International Congress: Reproductive Medicine and Beyond by ComtecMed
    04-Apr-13 to 06-Apr-13 Seville , SPAIN (GYN - Contraception & Reproductive Health)
     
  • 2013 AIUM Annual Convention by American Institute of Ultrasound in Medicine
    06-Apr-13 to 10-Apr-13 New York (New York Marriott Marquis Hotel) , NY USA (CME - Medical Education)
     
  • Manejo clínico y terapéutico de la esterilidad. Segundo curso online by Fundacio Dexeus Salud de la Mujer
    09-Apr-13 to 31-May-13 online , SPAIN(gynecology)
     
  • Pediatric Nursing: Care of the Hospitalized Child by Continuing Education Inc.
    10-Apr-13 to 13-Apr-13 Anaheim (Hyatt Regency Orange County) , CA USA (CME - Obstetrics, Gynecology & Women's Health)
     
  • Medicina fetal Curso-Taller. Curso de Nivel I y II de la SESEGO by Fundacio Dexeus Salud de la Mujer
    15-Apr-13 to 17-Apr-13 Barcelona (Auditorio Salud de la Mujer Dexeus) , SPAIN (OB - Maternal Fetal Medicine)
     
  • Female Urology & Urogynecology Symposium (FUUS) by Quadrant HealthCom, Inc
    18-Apr-13 to 20-Apr-13 Las Vegas (ARIA) , NV USA (CME - Obstetrics, Gynecology & Women's Health)
     
  • Female Urology and Urogynecology Symposium (FUUS) 2013 by Quadrant HealthCom, Inc
    18-Apr-13 to 20-Apr-13 Las Vegas (ARIA) , NV USA (CME - Obstetrics, Gynecology & Women's Health)

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy